A tool for analyzing how drugs selectively bind to targets
A Web Service for Fragment-based Selectivity Analysis of Drug Leads
This study is creating an easy-to-use online tool that helps scientists design better COVID-19 drugs by showing how different drug candidates connect with specific proteins, making it quicker and easier to find effective treatments.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Conifer Point Pharmaceuticals, LLC NIH-funded |
| Lab location | 1 site (Doylestown, United States) |
| Project ID | NIH-10927219 on NIH RePORTER |
What this research studies
This research focuses on developing a web-based tool that helps in the design of drugs by analyzing how they bind to specific proteins, particularly those related to COVID-19. The tool utilizes a large database of chemical fragment binding maps, which provides insights into the interactions between drug candidates and their targets. By leveraging cloud computing, the tool allows researchers to visualize binding patterns and suggest modifications to improve drug selectivity. This innovative approach aims to streamline the drug discovery process and enhance the development of effective medications.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals affected by COVID-19 or other conditions requiring targeted drug therapies.
Not a fit: Patients with conditions that do not involve the need for selective drug binding or those not affected by COVID-19 may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and selective drugs for treating COVID-19 and other diseases.
How similar studies have performed: Other research has shown success in using similar computational approaches for drug design, indicating a promising avenue for this innovative tool.
Where this research is happening
Doylestown, United States
- Conifer Point Pharmaceuticals, LLC — Doylestown, United States (Active)
Researchers
- Principal investigator: Kulp Iii, John Laurence — Conifer Point Pharmaceuticals, LLC
- Study coordinator: Kulp Iii, John Laurence
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.